RICHMOND, Va., April 30, 2002 (PRIMEZONE) -- A Biotech/Genomics Stocks Forum featuring five companies and an industry expert will be held on May 11. The event is open to the public and will take place at the Sheraton Suites in Alexandria, Virginia and online at www.informedinvestors.com. By attending this Forum, investors can hear directly from company executives and get their investment information straight from the source.
The event, produced by Informed Investors, will take place from 8 a.m. to 12 p.m. Information and registration are available at www.informedinvestors.com or by calling 888-301-6618.
Current and potential investors will hear from Biotech and Genomics sector companies including Genaissance Pharmaceuticals, Inc. (Nasdaq:GNSC) and GenVec (Nasdaq:GNVC). Executives from each company will give 20 minute analyst-style presentations, and a 5-10 minute question and answer session with the investor audience follows each presentation.
The keynote address will be delivered by Dennis E. Ohman, Ph.D. Dr. Ohman is the Chair of the Microbiology & Immunology Department at the Medical College of Virginia Campus of Virginia Commonwealth University. The department is highly research oriented, with a focus on cell and molecular biology, molecular genetics, and immunology. Dr. Ohman also serves as a Research Microbiologist at McGuire Medical Center.
Genaissance Pharmaceuticals, Inc. is the world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company discovers genetic markers (haplotypes) that are predictive of drug efficacy and safety, and markets its haplotype technology and its clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. The Company is also developing its own internal pipeline of products utilizing its proprietary genetic markers. Genaissance has agreements with three of the top ten pharmaceutical companies: Pfizer, AstraZeneca and Johnson & Johnson. Genaissance is located in Science Park in New Haven, Connecticut. They will be represented by Mr. Kevin Rakin, President and Chief Financial Officer at their 9:45 presentation.
GenVec will be speaking to investors at 11:30. GenVec develops gene-based products that cause the production of therapeutic proteins at the site of disease. GenVec's current areas of focus are cardiovascular disease, oncology and ophthalmology. GenVec's product candidates are comprised of genes and gene transfer systems that transport those genes into cells at the site of the disease.
Informed Investors is the leading producer of online and offline industry-specific investment conferences for individual investors and a member of the WILink family of companies serving self-reliant investors.
About WILink: Since 1992, WILink (www.wilink.com) has opened information channels between public companies and potential investors. WILink is an investor relations and investment services group that markets a range of services that help publicly traded companies and mutual funds attract and retain well informed investors, while providing investors with access to information to make well informed investment decisions. This year WILink will make more than 7 million investor introductions to over 4,200 corporate clients through services including The Annual Reports Service, The Fund Info Service, Vcall (www.vcall.com) Investor Conference (www.investorconference.com) and Informed Investors Forums (www.informedinvestors.com). These services provide investors free access to onsite and webcast investor events and company financial reports through WILink's relationships with over 220 leading financial media channels in 14 countries including The Wall Street Journal, Financial Times, Barron's and Yahoo!Finance. For companies and mutual funds, these services enable compliance with regulation fair-disclosure requirements and provide visibility with investors at the precise point investors are making decisions. WILink, Inc., a wholly owned subsidiary of WILink.com plc (WLK on The London Stock Exchange), began operations in Richmond, Va. in 1993.